0001225208-20-002600.txt : 20200218
0001225208-20-002600.hdr.sgml : 20200218
20200218160752
ACCESSION NUMBER: 0001225208-20-002600
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200214
FILED AS OF DATE: 20200218
DATE AS OF CHANGE: 20200218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ballinger Kevin J.
CENTRAL INDEX KEY: 0001566080
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 20625347
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC CORPORATION
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
4
1
doc4.xml
X0306
4
2020-02-14
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001566080
Ballinger Kevin J.
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
EVP & Pres, Interven Cardio
Common Stock
2020-02-14
4
A
0
27246.0000
0.0000
A
107331.0000
D
Common Stock
2020-02-14
4
F
0
11463.0000
42.3100
D
95868.0000
D
Common Stock
2020-02-15
4
M
0
3230.0000
0.0000
A
99098.0000
D
Common Stock
2020-02-15
4
F
0
1473.0000
42.3100
D
97625.0000
D
Deferred Stock Units
2020-02-15
4
M
0
3230.0000
0.0000
D
2023-02-15
Common Stock
3230.0000
9690.0000
D
On March 3, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
/s/ Scott G. Hodgdon, Attorney-in-Fact
2020-02-18